Related Experiment Video

Updated: Mar 5, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K

Sunitinib resistance in renal cell carcinoma

Christudas Morais1

  • 1Centre for Kidney Disease Research, School of Medicine, The University of Queensland at Translational Research Institute, Brisbane, Queensland 4102, Australia.

Journal of Kidney Cancer and VHL
|March 23, 2017
PubMed

Insights

Sunitinib is a common treatment for metastatic renal cell carcinoma (RCC), but resistance is a major challenge. Sequential therapy shows promise for overcoming both intrinsic and acquired sunitinib resistance in RCC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib is a primary first-line therapy for metastatic renal cell carcinoma (RCC).
  • Significant patient populations exhibit intrinsic resistance or develop acquired resistance to sunitinib.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the molecular mechanisms underlying intrinsic and acquired resistance to sunitinib in metastatic RCC.
  • To summarize current and emerging strategies for overcoming sunitinib resistance.
  • To highlight sequential therapy as a promising approach.

Main Methods:

  • Literature review of studies on sunitinib resistance in metastatic RCC.
  • Analysis of molecular mechanisms of intrinsic and acquired resistance.
  • Evaluation of therapeutic strategies including combination, rechallenge, and sequential therapy.

Main Results:

  • Intrinsic resistance mechanisms remain largely unknown, unlike acquired resistance.
  • Sequential therapy demonstrates potential as an effective strategy to overcome sunitinib resistance.
  • Combination and rechallenge therapies have also been explored.

Conclusions:

  • Sunitinib resistance in metastatic RCC necessitates novel therapeutic strategies.
  • Sequential therapy is a promising approach to manage both intrinsic and acquired resistance.
  • Further research into intrinsic resistance mechanisms is warranted.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
993
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K